Orthocell Ltd (ASX:OCC) has recruited and treated its first patient in a clinical trial of its Ortho-ATI® injection for the treatment of rotator cuff tendinopathy and tear in the shoulder.
Rotator cuff tendinopathy and tear (which manifests as severe shoulder pain) is a common and often difficult injury to treat and affects more than 50% of adults over 50 years of age.
The objective of this clinical trial is to assess the effectiveness of Autologous Tenocyte Injection (Ortho-ATI®) compared to corticosteroid injection in the treatment of rotator cuff tendinopathy and tear.
To be eligible for the trial, patients must have failed previous conservative treatment options, including previous injection treatment and physiotherapy.
Importantly, demonstrating the efficacy of Ortho-ATI® for the treatment of rotator cuff tendinopathy is an important element of Orthocell’s product development and partnering strategy.
In studies conducted by Orthocell to date, Ortho-ATI® has been shown to be a cost effective, durable, and non-surgical solution for difficult to treat tendon injuries.
Ortho-ATI® is available in Australia, New Zealand, and Hong Kong with regulatory oversight for patients who have failed conservative treatment options such as corticosteroid injections and exercise programs.
Rotator cuff injuries may lead to considerable disability, reduced quality of life, and absenteeism from work, and are a significant burden on healthcare resources.